![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases characterized by chronic muscle inflammation resulting in progressive weakness and frequent involvement of internal organs, mainly the pulmonary, gastrointestinal and cardiac systems which considerably contribute to the morbidity and mortality of the IIMs.
Aim of this study was to present clinical characteristics, disease course, frequency of relapses and survival in patients with juvenile dermatomyositis (DM).
A national registry of patients with juvenile IIMs was elaborated by the authors in Hungary. We have summarized data of the register according to signs and symptoms, disease course, frequency of relapses and survival of patients with juvenile IIM. Analysis was performed using data of 44 patients with juvenile DM diagnosed between 1976 and 2004 according to Bohan and Peter's criteria. Survival probability was calculated by Kaplan–Meier method.
Data of patients with juvenile DM were compared with data of 66 patients with adult DM. The most frequent cutaneous features were facial erythema and heliotrope rash. Extramuscular and extraskeletal manifestations of the disease were more frequent in adult patients. The most common extramuscular feature was arthralgia in both groups of patients with juvenile or adult DM. Cardiac manifestation of the disease was not observed in juvenile patients. Respiratory muscle involvement and interstitial lung disease (ILD) were more frequent among adult DM patients than cardiac manifestation of the myositis. In view of the disease course, the authors found that frequency of polycyclic and monophasic subtypes of the disease were mainly similar. The hazard of relapse was found higher during the first year after the remission. None of the juvenile patients died. Among adult patients four disease-specific deaths occurred. There was no correlation between relapse free survival and initial therapeutic regimen. Many of our patients had polycyclic or chronic disease. As relapses can occur after a prolonged disease-free interval, patients should be followed up for at least 2 years. Although we found favourable survival probability, further investigations are needed to assess functional outcome.
| Abbreviations | ||
| AZA | = | azathioprine |
| CAM | = | cancer-associated myositis |
| CK | = | creatinine-kinase |
| CYA | = | cyclosporine A |
| CYC | = | cyclophosphamide |
| CI | = | confidence interval |
| DM | = | dermatomyositis |
| HRCT | = | high-resolution computerized tomography |
| IIM | = | idiopathic inflammatory myopathy |
| ILD | = | interstitial lung disease |
| IVIG | = | intravenous immunoglobulin |
| LDH | = | lactate-acid dehydrogenase |
| MTX | = | methotrexate |
| OM | = | overlap myositis |
| PM | = | polymyositis |
| Abbreviations | ||
| AZA | = | azathioprine |
| CAM | = | cancer-associated myositis |
| CK | = | creatinine-kinase |
| CYA | = | cyclosporine A |
| CYC | = | cyclophosphamide |
| CI | = | confidence interval |
| DM | = | dermatomyositis |
| HRCT | = | high-resolution computerized tomography |
| IIM | = | idiopathic inflammatory myopathy |
| ILD | = | interstitial lung disease |
| IVIG | = | intravenous immunoglobulin |
| LDH | = | lactate-acid dehydrogenase |
| MTX | = | methotrexate |
| OM | = | overlap myositis |
| PM | = | polymyositis |